α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis
Open Access
- 22 April 2021
- journal article
- research article
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 134 (8)
Abstract
The α-arrestin domain containing protein 3 (ARRDC3) is a tumor suppressor in triple-negative breast carcinoma (TNBC), a highly metastatic subtype of breast cancer that lacks targeted therapies. Thus, understanding the mechanisms and targets of ARRDC3 in TNBC is important. ARRDC3 regulates trafficking of protease-activated receptor 1 (PAR1, also known as F2R), a G-protein-coupled receptor (GPCR) implicated in breast cancer metastasis. Loss of ARRDC3 causes overexpression of PAR1 and aberrant signaling. Moreover, dysregulation of GPCR-induced Hippo signaling is associated with breast cancer progression. However, the mechanisms responsible for Hippo dysregulation remain unknown. Here, we report that the Hippo pathway transcriptional co-activator TAZ (also known as WWTR1) is the major effector of GPCR signaling and is required for TNBC migration and invasion. Additionally, ARRDC3 suppresses PAR1-induced Hippo signaling via sequestration of TAZ, which occurs independently of ARRDC3-regulated PAR1 trafficking. The ARRDC3 C-terminal PPXY motifs and TAZ WW domain are crucial for this interaction and are required for suppression of TNBC migration and lung metastasis in vivo. These studies are the first to demonstrate a role for ARRDC3 in regulating GPCR-induced TAZ activity in TNBC and reveal multi-faceted tumor suppressor functions of ARRDC3. This article has an associated First Person interview with the first author of the paper.Keywords
Funding Information
- National Institutes of Health (R35 GM127121)
- Howard Hughes Medical Institute
This publication has 47 references indexed in Scilit:
- Proteomic Analyses Reveal Divergent Ubiquitylation Site Patterns in Murine TissuesMolecular & Cellular Proteomics, 2012
- Regulation of the Hippo–YAP pathway by protease-activated receptors (PARs)Genes & Development, 2012
- The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domainProceedings of the National Academy of Sciences, 2012
- ALIX binds a YPX3L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sortingJournal of Cell Biology, 2012
- The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer CellsCell, 2011
- Multiple Interactions between the ESCRT Machinery and Arrestin-Related Proteins: Implications for PPXY-Dependent BuddingJournal of Virology, 2011
- ARRDC3 suppresses breast cancer progression by negatively regulating integrin β4Oncogene, 2010
- TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo PathwayMolecular and Cellular Biology, 2008
- Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasionOncogene, 2008
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007